NW-3509: Additional Phase I data

Data from 54 healthy volunteers in a double-blind, placebo-controlled, U.S. Phase I trial showed that single doses of 1-30 mg oral NW-3509 were well tolerated. At the maximum tested dose of 30 mg NW-3...